SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-21-000536
Filing Date
2021-04-29
Accepted
2021-04-29 08:12:13
Documents
13
Period of Report
2021-04-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALNYLAM PHARMACEUTICALS, INC. 8-K a52420138.htm   iXBRL 8-K 25919
2 EXHIBIT 99.1 a52420138ex991.htm EX-99.1 203250
  Complete submission text file 0001157523-21-000536.txt   396948

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alny-20210429.xsd EX-101.SCH 4192
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20210429_lab.xml EX-101.LAB 23692
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20210429_pre.xml EX-101.PRE 16828
6 EXTRACTED XBRL INSTANCE DOCUMENT a52420138_htm.xml XML 4467
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 21867184
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences